🇺🇸 FDA
Pipeline program

Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

IM011-055

Phase 3 small_molecule active

Quick answer

Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets for Active Psoriatic Arthritis is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Active Psoriatic Arthritis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials